Clinical Trials
23 trialsNCT01601808 2025-03-13
ViP
University of Liverpool
Phase 2 Completed
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT06482086 2024-12-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Phase 2 Recruiting
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT01934335 2021-11-01
Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
University of Iowa
Phase 2 Terminated
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01414426 2021-01-14
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
University of Chicago
Phase 2 Completed
NCT01823068 2020-12-07
Vandetanib in Advanced NSCLC With RET Rearrangement
Samsung Medical Center
Phase 2 Completed
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT00613626 2020-02-11
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT01191892 2019-05-16
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Cardiff University
Phase 2 Completed
NCT00459121 2019-03-26
Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00880334 2018-09-18
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00687297 2018-05-30
Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
PrECOG, LLC.
Phase 2 Completed
NCT00481845 2017-02-07
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
Stanford University
Phase 2 Terminated
NCT00290537 2016-05-19
Phase II Study of ZD6474 in Advanced NSCLC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00402896 2016-03-09
Malignant Pleural Effusion With ZD6474
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00410189 2015-03-23
BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00683787 2015-01-08
Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00811369 2013-11-18
ZAMBONEY
Ontario Clinical Oncology Group (OCOG)
Phase 2 Completed
NCT00459043 2013-07-03
Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00757692 2013-02-20
Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
British Columbia Cancer Agency
Phase 2 Completed